In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18.

Autor:	Appalaraju B; Department of Microbiology, PSG Institute of Medical Sciences and Research, Peelamedu, Coimbatore, Tamil Nadu, India., Baveja S; Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Sion, Mumbai, India., Baliga S; Department of Microbiology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Karnataka, India., Shenoy S; Department of Microbiology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Karnataka, India., Bhardwaj R; Department of Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon Hospitals, Pune, Maharashtra, India., Kongre V; Department of Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon Hospitals, Pune, Maharashtra, India., Dattatraya GS; Department of Microbiology, DM Wayanad Institute of Medical Sciences, Wayanad, Kerala, India., Dhole T; Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India., Verma B; Department of Microbiology, Shree Jagannath Hospital & Research Centre, Ranchi Jharkhand, India., Mukherjee DN; Department of Microbiology, Woodlands Multispeciality Hospital Ltd, Kolkata, West Bengal, India., Gupta S; Department of Microbiology, Somani Hospital, Jaipur, Rajasthan, India., Shanmugam P; Department of Microbiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chennai, Tamil Nadu, India., Iravane J; Department of Microbiology, Government Medical College, Aurangabad, Maharashtra, India., Mishra SR; Department of Microbiology, Aditya Care Hospital, Bhubaneswar, Odisha, India., Barman P; Department of Microbiology, BLK Super Speciality Hospital, New Delhi, India., Chopra S; Department of Microbiology, BLK Super Speciality Hospital, New Delhi, India., Hariharan M; Department of Microbiology, Down Town Hospital, Guwahati, Assam, India., Surpam R; Department of Microbiology, Government Medical College and Hospital, Nagpur, Maharashtra, India., Pratap R; Department of Microbiology, Narayan Medical College and Hospital, Jamuhar, Bihar, India., Joshi P; Drug Discovery Research, Wockhardt Research Centre, Aurangabad, Maharashtra, India., Khande H; Drug Discovery Research, Wockhardt Research Centre, Aurangabad, Maharashtra, India., Mane A; Medical Affairs, Wockhardt Ltd, Mumbai, Maharashtra, India., Jain R; Medical Affairs, Wockhardt Ltd, Mumbai, Maharashtra, India., Bhagwat S; Drug Discovery Research, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Mar 01; Vol. 75 (3), pp. 600-608.
DOI:	10.1093/jac/dkz493
Abstrakt:	Background: Levonadifloxacin is a novel antibiotic belonging to the benzoquinolizine subclass of fluoroquinolones with potent activity against MRSA and quinolone-resistant Staphylococcus aureus. IV levonadifloxacin and its oral prodrug alalevonadifloxacin have recently been approved in India for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) including diabetic foot infections. Objectives: To investigate the in vitro activity of levonadifloxacin against contemporary clinical isolates collected from multiple tertiary care hospitals across India in the Antimicrobial Susceptibility Profiling of Indian Resistotypes (ASPIRE) surveillance study. Methods: A total of 1376 clinical isolates, consisting of staphylococci (n = 677), streptococci (n = 178), Enterobacterales (n = 320), Pseudomonas aeruginosa (n = 140) and Acinetobacter baumannii (n = 61), collected (2016-18) from 16 tertiary hospitals located across 12 states in India, were included in the study. The MICs of levonadifloxacin and comparator antibiotics were determined using the reference agar dilution method and broth microdilution method. Results: Levonadifloxacin exhibited potent activity against MSSA (MIC50/90: 0.5/1 mg/L), MRSA (MIC50/90: 0.5/1 mg/L) and levofloxacin-resistant S. aureus (MIC50/90: 1/1 mg/L) isolates. Similarly, potent activity of levonadifloxacin was also observed against CoNS including MDR isolates (MIC50/90: 1/2 mg/L). Against Streptococcus pneumoniae, levonadifloxacin (MIC50/90: 0.5/0.5 mg/L) showed superior activity compared with levofloxacin (MIC50/90: 1/2 mg/L). Among levofloxacin-susceptible Enterobacterales, 80.6% of isolates were inhibited at ≤2 mg/L levonadifloxacin. Conclusions: Levonadifloxacin displayed potent activity against contemporary MRSA and fluoroquinolone-resistant staphylococcal isolates, thus offering a valuable IV as well as an oral therapeutic option for the treatment of ABSSSIs. Furthermore, levonadifloxacin exhibited a broad-spectrum activity profile as evident from its activity against streptococci and levofloxacin-susceptible Gram-negative isolates. (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu